Role of homocysteine in end-stage renal disease

Chia Chao Wu, Cai Mei Zheng, Yuh Feng Lin, Lan Lo, Min Tser Liao, Kuo Cheng Lu

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Patients on dialysis have a substantially higher mortality rate compared with the general population. Dialysis is usually associated with an increased plasma level of homocysteine (Hcy). Hcy is viewed as a nontraditional marker of the prognosis of cardiovascular disease (CVD) in the general population and in patients with chronic kidney disease. The effects of Hcy-lowering therapy in patients with end-stage renal disease (ESRD) remain controversial. We searched multiple databases including PubMed, MEDLINE, and OVID, and conducted a systematic review of the literature. Possible therapeutic measures were also surveyed. Our review shows that effective normalization of plasma Hcy level may decrease CVD-related morbidity and mortality in nondiabetic ESRD patients. Hyperglycemia in association with diabetes mellitus makes ESRD patients resistant to Hcy-lowering therapy. Folic acid fortification may attenuate the beneficial effects of Hcy-lowering therapy. Supraphysiological doses of folic acid and vitamin B supplementation might be needed in ESRD patients with diabetes or high Hcy levels. The response to Hcy-lowering therapy may be influenced by differences within and between populations in sex, genotype, nutrition, and mandatory fortification. Treatment resistance found mainly in diabetic ESRD patients but not in nondiabetic ESRD patients that may need other therapeutic approaches.

Original languageEnglish
Pages (from-to)1286-1294
Number of pages9
JournalClinical Biochemistry
Volume45
Issue number16-17
DOIs
Publication statusPublished - Nov 2012

Fingerprint

Homocysteine
Chronic Kidney Failure
Dialysis
Folic Acid
Medical problems
Therapeutics
Cardiovascular Diseases
Population
Vitamin B Complex
Plasmas
Mortality
Chronic Renal Insufficiency
PubMed
MEDLINE
Hyperglycemia
Nutrition
Diabetes Mellitus
Genotype
Databases
Morbidity

Keywords

  • Diabetes
  • Dialysis
  • End-stage renal disease
  • Folic acid
  • Homocysteine

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Role of homocysteine in end-stage renal disease. / Wu, Chia Chao; Zheng, Cai Mei; Lin, Yuh Feng; Lo, Lan; Liao, Min Tser; Lu, Kuo Cheng.

In: Clinical Biochemistry, Vol. 45, No. 16-17, 11.2012, p. 1286-1294.

Research output: Contribution to journalArticle

Wu, Chia Chao ; Zheng, Cai Mei ; Lin, Yuh Feng ; Lo, Lan ; Liao, Min Tser ; Lu, Kuo Cheng. / Role of homocysteine in end-stage renal disease. In: Clinical Biochemistry. 2012 ; Vol. 45, No. 16-17. pp. 1286-1294.
@article{b92039b44e724b24b2cc3957b2238909,
title = "Role of homocysteine in end-stage renal disease",
abstract = "Patients on dialysis have a substantially higher mortality rate compared with the general population. Dialysis is usually associated with an increased plasma level of homocysteine (Hcy). Hcy is viewed as a nontraditional marker of the prognosis of cardiovascular disease (CVD) in the general population and in patients with chronic kidney disease. The effects of Hcy-lowering therapy in patients with end-stage renal disease (ESRD) remain controversial. We searched multiple databases including PubMed, MEDLINE, and OVID, and conducted a systematic review of the literature. Possible therapeutic measures were also surveyed. Our review shows that effective normalization of plasma Hcy level may decrease CVD-related morbidity and mortality in nondiabetic ESRD patients. Hyperglycemia in association with diabetes mellitus makes ESRD patients resistant to Hcy-lowering therapy. Folic acid fortification may attenuate the beneficial effects of Hcy-lowering therapy. Supraphysiological doses of folic acid and vitamin B supplementation might be needed in ESRD patients with diabetes or high Hcy levels. The response to Hcy-lowering therapy may be influenced by differences within and between populations in sex, genotype, nutrition, and mandatory fortification. Treatment resistance found mainly in diabetic ESRD patients but not in nondiabetic ESRD patients that may need other therapeutic approaches.",
keywords = "Diabetes, Dialysis, End-stage renal disease, Folic acid, Homocysteine",
author = "Wu, {Chia Chao} and Zheng, {Cai Mei} and Lin, {Yuh Feng} and Lan Lo and Liao, {Min Tser} and Lu, {Kuo Cheng}",
year = "2012",
month = "11",
doi = "10.1016/j.clinbiochem.2012.05.031",
language = "English",
volume = "45",
pages = "1286--1294",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "16-17",

}

TY - JOUR

T1 - Role of homocysteine in end-stage renal disease

AU - Wu, Chia Chao

AU - Zheng, Cai Mei

AU - Lin, Yuh Feng

AU - Lo, Lan

AU - Liao, Min Tser

AU - Lu, Kuo Cheng

PY - 2012/11

Y1 - 2012/11

N2 - Patients on dialysis have a substantially higher mortality rate compared with the general population. Dialysis is usually associated with an increased plasma level of homocysteine (Hcy). Hcy is viewed as a nontraditional marker of the prognosis of cardiovascular disease (CVD) in the general population and in patients with chronic kidney disease. The effects of Hcy-lowering therapy in patients with end-stage renal disease (ESRD) remain controversial. We searched multiple databases including PubMed, MEDLINE, and OVID, and conducted a systematic review of the literature. Possible therapeutic measures were also surveyed. Our review shows that effective normalization of plasma Hcy level may decrease CVD-related morbidity and mortality in nondiabetic ESRD patients. Hyperglycemia in association with diabetes mellitus makes ESRD patients resistant to Hcy-lowering therapy. Folic acid fortification may attenuate the beneficial effects of Hcy-lowering therapy. Supraphysiological doses of folic acid and vitamin B supplementation might be needed in ESRD patients with diabetes or high Hcy levels. The response to Hcy-lowering therapy may be influenced by differences within and between populations in sex, genotype, nutrition, and mandatory fortification. Treatment resistance found mainly in diabetic ESRD patients but not in nondiabetic ESRD patients that may need other therapeutic approaches.

AB - Patients on dialysis have a substantially higher mortality rate compared with the general population. Dialysis is usually associated with an increased plasma level of homocysteine (Hcy). Hcy is viewed as a nontraditional marker of the prognosis of cardiovascular disease (CVD) in the general population and in patients with chronic kidney disease. The effects of Hcy-lowering therapy in patients with end-stage renal disease (ESRD) remain controversial. We searched multiple databases including PubMed, MEDLINE, and OVID, and conducted a systematic review of the literature. Possible therapeutic measures were also surveyed. Our review shows that effective normalization of plasma Hcy level may decrease CVD-related morbidity and mortality in nondiabetic ESRD patients. Hyperglycemia in association with diabetes mellitus makes ESRD patients resistant to Hcy-lowering therapy. Folic acid fortification may attenuate the beneficial effects of Hcy-lowering therapy. Supraphysiological doses of folic acid and vitamin B supplementation might be needed in ESRD patients with diabetes or high Hcy levels. The response to Hcy-lowering therapy may be influenced by differences within and between populations in sex, genotype, nutrition, and mandatory fortification. Treatment resistance found mainly in diabetic ESRD patients but not in nondiabetic ESRD patients that may need other therapeutic approaches.

KW - Diabetes

KW - Dialysis

KW - End-stage renal disease

KW - Folic acid

KW - Homocysteine

UR - http://www.scopus.com/inward/record.url?scp=84868301351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868301351&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2012.05.031

DO - 10.1016/j.clinbiochem.2012.05.031

M3 - Article

C2 - 22683753

AN - SCOPUS:84868301351

VL - 45

SP - 1286

EP - 1294

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 16-17

ER -